The new high-density chips could give Roche NimbleGen an advantage in the market for clinical research arrays, such as cytogenetics, where it competes against Affymetrix, Agilent Technologies, and Illumina.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.